{"success":true,"data":{"pressRelease":{"id":"148278","rtpr_id":"nPn20wMDQa-20260921","ticker":"ARMP","exchange":"NYSE American","all_tickers":["ARMP"],"title":"Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates","author":"PR Newswire","published_at":"2026-09-21T11:00:06.148Z","article_body":"Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates\nPR Newswire\n\nLOS ANGELES, Sept. 21, 2026\n\nControlled manufacturing reproducibly maintains defined genetic diversity\nacross AP-SA02 clinical drug product lots\n\nOral presentation scheduled for today Monday, Sept. 21, 2026 at the 20(th)\nInternational Symposium on Staphylococci and Staphylococcal Infections\n\nLOS ANGELES, Sept. 21, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE\nAmerican: ARMP) (\"Armata\" or the \"Company\"), a late clinical-stage\nbiotechnology company focused on the development of high-purity and potency,\npathogen-specific bacteriophage therapeutics for the treatment of\nantibiotic-resistant and difficult-to-treat bacterial infections, today\nannounced it will present data showing that defined, controlled genetic\ndiversity within AP-SA02 may enhance the product's ability to kill certain\nStaphylococcus aureus (\"S. aureus\") clinical isolates. Importantly, Armata\ndeliberately maintains this defined genetic diversity as an important product\nattribute through controlled manufacturing across clinical drug product lots\nof AP-SA02. AP-SA02 is Armata's investigational bacteriophage cocktail being\ndeveloped as an adjunct treatment for complicated bacteremia caused by\nmethicillin-sensitive S. aureus (\"MSSA\") or methicillin-resistant S.\naureus (\"MRSA\"). The findings will be presented today in an oral session at\nthe 2026 International Symposium on Staphylococci and Staphylococcal\nInfections\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4777372-1&h=3956789796&u=https%3A%2F%2Fbanff.isssi2026.com%2Fevent%2FISSSI%2F2026&a=2026+International+Symposium+on+Staphylococci+and+Staphylococcal+Infections)\n (\"ISSSI 2026\"), which is being held September 20-24, 2026 in Banff, Alberta,\nCanada.\n\nGenomic analyses showed that AP-SA02 contains a defined and reproducible\nprofile of genetic variants. Specifically, when one of its component phages\nwas grown in vitro on S. aureus isolates collected during the Phase 1b/2a\ndiSArm study, select variants became enriched depending on the isolate,\nsuggesting that certain variants were better able to infect and replicate on\nparticular clinical isolates. In a separate experiment, a phage stock lacking\nthese variants showed reduced activity against select clinical isolates,\nfurther supporting functional relevance of the variants. Based on these\nfindings, Armata uses controlled manufacturing conditions to reproducibly\nmaintain the defined genetic variants across clinical drug product lots,\nmaking this genetic diversity an intentionally controlled attribute of AP-SA02\ndrug product.\n\nTogether, the genomic and functional data support controlled genetic diversity\nas an important product attribute that may improve the performance of AP-SA02\nagainst certain isolates within its broad MRSA and MSSA activity profile. The\nin vitro findings complement the positive results from the Phase 2a diSArm\nstudy, in which 100% of AP-SA02-treated participants with an evaluable\nend-of-study assessment achieved a complete clinical response.\n\n\"These findings provide important mechanistic support for what we believe is a\nkey attribute of AP-SA02: controlled genomic diversity that enables the\nindividual phages in the cocktail to adapt to and kill a broad range of\ngenetically and geographically diverse MRSA and MSSA clinical isolates,\" said\nDr. Deborah Birx, Chief Executive Officer of Armata. \"Importantly, the\ndiversity profile is defined and reproducible across clinical drug product\nlots of AP-SA02. Together with the 100% clinical response observed in our\nPhase 2a diSArm study, these data further strengthen our confidence in the\nprogram as we advance AP-SA02 toward a Phase 3 superiority study in\ncomplicated S. aureus bacteremia.\"\n\nPresentation Details\n Conference:     20(th) International Symposium on Staphylococci and Staphylococcal Infections\n                 (ISSSI 2026), September 20-24, 2026\n Title:          Controlled genomic diversity in AP-SA02 bacteriophage cocktail enables\n                 adaptive amplification across diverse Staphylococcus aureus isolates\n Presenter:      Renae Geier, Senior Scientist, Genomics, Armata Pharmaceuticals\n Session:        Podium Session 2: Antistaphylococcals\n Date and Time:  Monday, Sept. 21, 2026, 5:25 p.m. to 5:40 p.m. MDT\n Location:       Banff Centre for Arts and Creativity, Banff, Alberta, Canada\n\nAbout AP-SA02\n\nArmata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct\ntreatment of complicated Staphylococcus aureus bacteremia caused by\nmethicillin-sensitive S. aureus (MSSA) or methicillin-resistant S.\naureus (MRSA). AP-SA02 has received Qualified Infectious Disease Product\n(QIDP)\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4777372-1&h=546392820&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Farmata-pharmaceuticals-receives-fda-qualified-infectious-disease-product-qidp-designation-for-ap-sa02-302694147.html&a=Qualified+Infectious+Disease+Product+(QIDP))\n, Fast Track\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4777372-1&h=1807188528&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Farmata-pharmaceuticals-secures-fda-fast-track-designation-for-ap-sa02-302764421.html&a=Fast+Track)\n, and Breakthrough Therapy\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4777372-1&h=1777299442&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Farmata-pharmaceuticals-receives-us-fda-breakthrough-therapy-designation-for-ap-sa02-302877051.html&a=Breakthrough+Therapy)\n designations from the FDA. The diSArm study (NCT05184764) was a Phase 1b/2a,\nmulticenter, randomized, double-blind, placebo-controlled, multiple ascending\ndose escalation study of the safety, tolerability, and efficacy of intravenous\nAP-SA02 in addition to best available antibiotic therapy (\"BAT\") compared to\nBAT alone (placebo) for the treatment of adults with complicated S.\naureus bacteremia. Positive results\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4777372-1&h=2611696094&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Farmata-pharmaceuticals-highlights-positive-results-from-phase-2a-disarm-study-of-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-in-late-breaking-oral-presentation-at-idweek-2025-302590906.html&a=Positive+results)\n from the Phase 2a diSArm study were highlighted in a late-breaking oral\npresentation at IDWeek 2025™\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4777372-1&h=3590530573&u=https%3A%2F%2Ffilecache.investorroom.com%2Fmr5ir_armatapharma%2F187%2FArmata_Dr_Loren_Miller_IDWeek_2025_Late-Breaking_Oral_Presentation.pdf&a=late-breaking+oral+presentation+at+IDWeek+2025%E2%84%A2)\n in October 2025. The Company plans to advance AP-SA02 into a Phase 3\nsuperiority study in complicated SAB, anticipated to initiate in the second\nhalf of 2026.\n\nAbout Armata Pharmaceuticals, Inc.\n\nArmata is a late clinical-stage biotechnology company focused on the\ndevelopment of high-purity and potency, pathogen-specific bacteriophage\ntherapeutics for the treatment of antibiotic-resistant and difficult-to-treat\nbacterial infections using its proprietary bacteriophage-based technology.\nArmata is developing and advancing a broad pipeline of natural and synthetic\nphage candidates, including clinical candidates for Pseudomonas aeruginosa,\nStaphylococcus aureus, and other important pathogens. Armata is committed to\nadvancing phage therapy with drug development expertise that spans bench to\nclinic including in-house phage-specific current Good Manufacturing Practices\n(\"cGMP\") manufacturing to support full commercialization.\n\nForward Looking Statements\n\nThis communication contains \"forward-looking\" statements as defined by the\nPrivate Securities Litigation Reform Act of 1995. These statements relate to\nfuture events, results or to Armata's future financial performance and involve\nknown and unknown risks, uncertainties and other factors which may cause\nArmata's actual results, performance or events to be materially different from\nany future results, performance or events expressed or implied by the\nforward-looking statements. In some cases, you can identify these statements\nby terms such as \"anticipate,\" \"believe,\" \"could,\" \"estimate,\" \"expect,\"\n\"intend,\" \"may,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"will,\"\n\"would\" or the negative of those terms, and similar expressions. These\nforward-looking statements reflect management's beliefs and views with respect\nto future events and are based on estimates and assumptions as of the date of\nthis communication and are subject to risks and uncertainties including risks\nrelated to Armata's development of bacteriophage-based therapies; Armata's\nplanned clinical trials; ability to staff and maintain its production\nfacilities under fully compliant cGMP; ability to meet anticipated milestones\nin the development and testing of the relevant product; ability to be a leader\nin the development of phage-based therapeutics; ability to achieve its vision,\nincluding improvements through engineering and success of clinical trials;\nability to successfully complete preclinical and clinical development of, and\nobtain regulatory approval of its product candidates and commercialize any\napproved products on its expected timeframes or at all; and Armata's estimates\nregarding anticipated operating losses, capital requirements and needs for\nadditional funds. Additional risks and uncertainties relating to Armata and\nits business can be found under the caption \"Risk Factors\" and elsewhere in\nArmata's filings and reports with the U.S. Securities and Exchange Commission\n(the \"SEC\"), including in Armata's Annual Report on Form 10-K, filed with the\nSEC on March 25, 2026, and in its subsequent filings with the SEC.\n\nArmata expressly disclaims any obligation or undertaking to release publicly\nany updates or revisions to any forward-looking statements contained herein to\nreflect any change in Armata's expectations with regard thereto or any change\nin events, conditions or circumstances on which any such statements are\nbased.\n\nMedia Contacts:\n\nAt Armata:\n\nPierre Kyme\nir@armatapharma.com (mailto:ir@armatapharma.com)\n310-665-2928\n\nInvestor Relations:\n\nJoyce Allaire\nLifeSci Advisors, LLC\njallaire@lifesciadvisors.com (mailto:jallaire@lifesciadvisors.com)\n212-915-2569\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-present-data-at-isssi-2026-showing-defined-genetic-diversity-in-ap-sa02-may-enhance-killing-of-certain-staphylococcus-aureus-clinical-isolates-302882676.html\n(https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-present-data-at-isssi-2026-showing-defined-genetic-diversity-in-ap-sa02-may-enhance-killing-of-certain-staphylococcus-aureus-clinical-isolates-302882676.html)\n\nSOURCE Armata Pharmaceuticals, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1169688/Armata-Logo.jpg?id=OA2956591\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nPn20wMDQa-20260921","title":"Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates","author":"PR Newswire","ticker":"ARMP","created":"2026-09-21T11:00:06.148Z","tickers":["ARMP"],"exchange":"NYSE American","article_body":"Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates\nPR Newswire\n\nLOS ANGELES, Sept. 21, 2026\n\nControlled manufacturing reproducibly maintains defined genetic diversity\nacross AP-SA02 clinical drug product lots\n\nOral presentation scheduled for today Monday, Sept. 21, 2026 at the 20(th)\nInternational Symposium on Staphylococci and Staphylococcal Infections\n\nLOS ANGELES, Sept. 21, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE\nAmerican: ARMP) (\"Armata\" or the \"Company\"), a late clinical-stage\nbiotechnology company focused on the development of high-purity and potency,\npathogen-specific bacteriophage therapeutics for the treatment of\nantibiotic-resistant and difficult-to-treat bacterial infections, today\nannounced it will present data showing that defined, controlled genetic\ndiversity within AP-SA02 may enhance the product's ability to kill certain\nStaphylococcus aureus (\"S. aureus\") clinical isolates. Importantly, Armata\ndeliberately maintains this defined genetic diversity as an important product\nattribute through controlled manufacturing across clinical drug product lots\nof AP-SA02. AP-SA02 is Armata's investigational bacteriophage cocktail being\ndeveloped as an adjunct treatment for complicated bacteremia caused by\nmethicillin-sensitive S. aureus (\"MSSA\") or methicillin-resistant S.\naureus (\"MRSA\"). The findings will be presented today in an oral session at\nthe 2026 International Symposium on Staphylococci and Staphylococcal\nInfections\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4777372-1&h=3956789796&u=https%3A%2F%2Fbanff.isssi2026.com%2Fevent%2FISSSI%2F2026&a=2026+International+Symposium+on+Staphylococci+and+Staphylococcal+Infections)\n (\"ISSSI 2026\"), which is being held September 20-24, 2026 in Banff, Alberta,\nCanada.\n\nGenomic analyses showed that AP-SA02 contains a defined and reproducible\nprofile of genetic variants. Specifically, when one of its component phages\nwas grown in vitro on S. aureus isolates collected during the Phase 1b/2a\ndiSArm study, select variants became enriched depending on the isolate,\nsuggesting that certain variants were better able to infect and replicate on\nparticular clinical isolates. In a separate experiment, a phage stock lacking\nthese variants showed reduced activity against select clinical isolates,\nfurther supporting functional relevance of the variants. Based on these\nfindings, Armata uses controlled manufacturing conditions to reproducibly\nmaintain the defined genetic variants across clinical drug product lots,\nmaking this genetic diversity an intentionally controlled attribute of AP-SA02\ndrug product.\n\nTogether, the genomic and functional data support controlled genetic diversity\nas an important product attribute that may improve the performance of AP-SA02\nagainst certain isolates within its broad MRSA and MSSA activity profile. The\nin vitro findings complement the positive results from the Phase 2a diSArm\nstudy, in which 100% of AP-SA02-treated participants with an evaluable\nend-of-study assessment achieved a complete clinical response.\n\n\"These findings provide important mechanistic support for what we believe is a\nkey attribute of AP-SA02: controlled genomic diversity that enables the\nindividual phages in the cocktail to adapt to and kill a broad range of\ngenetically and geographically diverse MRSA and MSSA clinical isolates,\" said\nDr. Deborah Birx, Chief Executive Officer of Armata. \"Importantly, the\ndiversity profile is defined and reproducible across clinical drug product\nlots of AP-SA02. Together with the 100% clinical response observed in our\nPhase 2a diSArm study, these data further strengthen our confidence in the\nprogram as we advance AP-SA02 toward a Phase 3 superiority study in\ncomplicated S. aureus bacteremia.\"\n\nPresentation Details\n Conference:     20(th) International Symposium on Staphylococci and Staphylococcal Infections\n                 (ISSSI 2026), September 20-24, 2026\n Title:          Controlled genomic diversity in AP-SA02 bacteriophage cocktail enables\n                 adaptive amplification across diverse Staphylococcus aureus isolates\n Presenter:      Renae Geier, Senior Scientist, Genomics, Armata Pharmaceuticals\n Session:        Podium Session 2: Antistaphylococcals\n Date and Time:  Monday, Sept. 21, 2026, 5:25 p.m. to 5:40 p.m. MDT\n Location:       Banff Centre for Arts and Creativity, Banff, Alberta, Canada\n\nAbout AP-SA02\n\nArmata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct\ntreatment of complicated Staphylococcus aureus bacteremia caused by\nmethicillin-sensitive S. aureus (MSSA) or methicillin-resistant S.\naureus (MRSA). AP-SA02 has received Qualified Infectious Disease Product\n(QIDP)\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4777372-1&h=546392820&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Farmata-pharmaceuticals-receives-fda-qualified-infectious-disease-product-qidp-designation-for-ap-sa02-302694147.html&a=Qualified+Infectious+Disease+Product+(QIDP))\n, Fast Track\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4777372-1&h=1807188528&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Farmata-pharmaceuticals-secures-fda-fast-track-designation-for-ap-sa02-302764421.html&a=Fast+Track)\n, and Breakthrough Therapy\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4777372-1&h=1777299442&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Farmata-pharmaceuticals-receives-us-fda-breakthrough-therapy-designation-for-ap-sa02-302877051.html&a=Breakthrough+Therapy)\n designations from the FDA. The diSArm study (NCT05184764) was a Phase 1b/2a,\nmulticenter, randomized, double-blind, placebo-controlled, multiple ascending\ndose escalation study of the safety, tolerability, and efficacy of intravenous\nAP-SA02 in addition to best available antibiotic therapy (\"BAT\") compared to\nBAT alone (placebo) for the treatment of adults with complicated S.\naureus bacteremia. Positive results\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4777372-1&h=2611696094&u=https%3A%2F%2Fwww.prnewswire.com%2Fnews-releases%2Farmata-pharmaceuticals-highlights-positive-results-from-phase-2a-disarm-study-of-its-staphylococcus-aureus-bacteriophage-cocktail-ap-sa02-in-late-breaking-oral-presentation-at-idweek-2025-302590906.html&a=Positive+results)\n from the Phase 2a diSArm study were highlighted in a late-breaking oral\npresentation at IDWeek 2025™\n(https://edge.prnewswire.com/c/link/?t=0&l=en&o=4777372-1&h=3590530573&u=https%3A%2F%2Ffilecache.investorroom.com%2Fmr5ir_armatapharma%2F187%2FArmata_Dr_Loren_Miller_IDWeek_2025_Late-Breaking_Oral_Presentation.pdf&a=late-breaking+oral+presentation+at+IDWeek+2025%E2%84%A2)\n in October 2025. The Company plans to advance AP-SA02 into a Phase 3\nsuperiority study in complicated SAB, anticipated to initiate in the second\nhalf of 2026.\n\nAbout Armata Pharmaceuticals, Inc.\n\nArmata is a late clinical-stage biotechnology company focused on the\ndevelopment of high-purity and potency, pathogen-specific bacteriophage\ntherapeutics for the treatment of antibiotic-resistant and difficult-to-treat\nbacterial infections using its proprietary bacteriophage-based technology.\nArmata is developing and advancing a broad pipeline of natural and synthetic\nphage candidates, including clinical candidates for Pseudomonas aeruginosa,\nStaphylococcus aureus, and other important pathogens. Armata is committed to\nadvancing phage therapy with drug development expertise that spans bench to\nclinic including in-house phage-specific current Good Manufacturing Practices\n(\"cGMP\") manufacturing to support full commercialization.\n\nForward Looking Statements\n\nThis communication contains \"forward-looking\" statements as defined by the\nPrivate Securities Litigation Reform Act of 1995. These statements relate to\nfuture events, results or to Armata's future financial performance and involve\nknown and unknown risks, uncertainties and other factors which may cause\nArmata's actual results, performance or events to be materially different from\nany future results, performance or events expressed or implied by the\nforward-looking statements. In some cases, you can identify these statements\nby terms such as \"anticipate,\" \"believe,\" \"could,\" \"estimate,\" \"expect,\"\n\"intend,\" \"may,\" \"plan,\" \"potential,\" \"predict,\" \"project,\" \"should,\" \"will,\"\n\"would\" or the negative of those terms, and similar expressions. These\nforward-looking statements reflect management's beliefs and views with respect\nto future events and are based on estimates and assumptions as of the date of\nthis communication and are subject to risks and uncertainties including risks\nrelated to Armata's development of bacteriophage-based therapies; Armata's\nplanned clinical trials; ability to staff and maintain its production\nfacilities under fully compliant cGMP; ability to meet anticipated milestones\nin the development and testing of the relevant product; ability to be a leader\nin the development of phage-based therapeutics; ability to achieve its vision,\nincluding improvements through engineering and success of clinical trials;\nability to successfully complete preclinical and clinical development of, and\nobtain regulatory approval of its product candidates and commercialize any\napproved products on its expected timeframes or at all; and Armata's estimates\nregarding anticipated operating losses, capital requirements and needs for\nadditional funds. Additional risks and uncertainties relating to Armata and\nits business can be found under the caption \"Risk Factors\" and elsewhere in\nArmata's filings and reports with the U.S. Securities and Exchange Commission\n(the \"SEC\"), including in Armata's Annual Report on Form 10-K, filed with the\nSEC on March 25, 2026, and in its subsequent filings with the SEC.\n\nArmata expressly disclaims any obligation or undertaking to release publicly\nany updates or revisions to any forward-looking statements contained herein to\nreflect any change in Armata's expectations with regard thereto or any change\nin events, conditions or circumstances on which any such statements are\nbased.\n\nMedia Contacts:\n\nAt Armata:\n\nPierre Kyme\nir@armatapharma.com (mailto:ir@armatapharma.com)\n310-665-2928\n\nInvestor Relations:\n\nJoyce Allaire\nLifeSci Advisors, LLC\njallaire@lifesciadvisors.com (mailto:jallaire@lifesciadvisors.com)\n212-915-2569\n\nView original content to download\nmultimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-present-data-at-isssi-2026-showing-defined-genetic-diversity-in-ap-sa02-may-enhance-killing-of-certain-staphylococcus-aureus-clinical-isolates-302882676.html\n(https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-present-data-at-isssi-2026-showing-defined-genetic-diversity-in-ap-sa02-may-enhance-killing-of-certain-staphylococcus-aureus-clinical-isolates-302882676.html)\n\nSOURCE Armata Pharmaceuticals, Inc.\n\n\n\nPhoto: \nhttps://mmx.prnewswire.com/media/MS1169688/Armata-Logo.jpg?id=OA2956591\n\nCopyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved."},"type":"article","timestamp":"2026-09-21T11:00:06.189783943Z","server_sent_at_ms":1789988406189},"received_at":"2026-09-21T11:00:06.258Z","source_url":"https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-present-data-at-isssi-2026-showing-defined-genetic-diversity-in-ap-sa02-may-enhance-killing-of-certain-staphylococcus-aureus-clinical-isolates-302882676.html"},"analysis":{"id":"137719","press_release_id":"148278","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Data presented are in vitro only; no new clinical endpoints reported in this release (Phase 2a results were previously disclosed)"],"eventType":"clinical_trial","narrative":"Armata Pharmaceuticals will present data at ISSSI 2026 showing that defined, controlled genetic diversity in its lead bacteriophage cocktail AP-SA02 may enhance killing of certain Staphylococcus aureus clinical isolates, including MRSA and MSSA.\n\nGenomic analyses identified a reproducible profile of genetic variants across clinical drug product lots, and the company deliberately maintains this diversity through controlled manufacturing as an intentional product attribute.\n\nThe in vitro findings complement the Phase 2a diSArm study, in which 100% of evaluable AP-SA02-treated participants achieved a complete clinical response, and support the planned Phase 3 superiority study in complicated S. aureus bacteremia expected to initiate in the second half of 2026.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Mechanistic support for AP-SA02's manufacturing-controlled phage diversity as the program advances toward a Phase 3 start in H2 2026."},"keyFigures":{"drugName":"AP-SA02","phaseOfTrial":"Phase 2a (diSArm); Phase 3 planned","customDimensions":{"conference":"ISSSI 2026, September 20-24, 2026, Banff, Alberta, Canada","phase3_timing":"second half of 2026","regulatory_designations":["QIDP","Fast Track","Breakthrough Therapy"],"phase2a_complete_response_rate":"100% of evaluable participants achieved complete clinical response"}},"quotedText":"These findings provide important mechanistic support for what we believe is a key attribute of AP-SA02: controlled genomic diversity that enables the individual phages in the cocktail to adapt to and kill a broad range of genetically and geographically diverse MRSA and MSSA clinical isolates","namedEntities":{"people":[{"name":"Dr. Deborah Birx","role":"Chief Executive Officer of Armata"},{"name":"Renae Geier","role":"Senior Scientist, Genomics, Armata Pharmaceuticals (presenter)"}],"products":["AP-SA02"],"companies":[{"name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","relationship":"filer/issuer"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Conference presentation of in vitro mechanistic data supporting the lead clinical candidate AP-SA02; no new clinical results, regulatory decisions, or financial events. Modestly supportive ahead of the planned Phase 3 start in H2 2026."},"tickerRelevance":{"others":[],"primary":"ARMP"},"globalImportance":18,"audienceRelevance":12,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap clinical-stage biotech","eventGravity":"conference-data-presentation","sectorWeight":"healthcare","issuerAuthored":true,"newClinicalData":false,"programStageContext":"Phase 3-ready lead asset, supportive but incremental data"}},"event_type":"clinical_trial","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Armata Pharmaceuticals will present data at ISSSI 2026 showing that defined, controlled genetic diversity in its lead bacteriophage cocktail AP-SA02 may enhance killing of certain Staphylococcus aureus clinical isolates, including MRSA and MSSA.\n\nGenomic analyses identified a reproducible profile of genetic variants across clinical drug product lots, and the company deliberately maintains this diversity through controlled manufacturing as an intentional product attribute.\n\nThe in vitro findings complement the Phase 2a diSArm study, in which 100% of evaluable AP-SA02-treated participants achieved a complete clinical response, and support the planned Phase 3 superiority study in complicated S. aureus bacteremia expected to initiate in the second half of 2026.","key_figures":{"drugName":"AP-SA02","phaseOfTrial":"Phase 2a (diSArm); Phase 3 planned","customDimensions":{"conference":"ISSSI 2026, September 20-24, 2026, Banff, Alberta, Canada","phase3_timing":"second half of 2026","regulatory_designations":["QIDP","Fast Track","Breakthrough Therapy"],"phase2a_complete_response_rate":"100% of evaluable participants achieved complete clinical response"}},"named_entities":{"people":[{"name":"Dr. Deborah Birx","role":"Chief Executive Officer of Armata"},{"name":"Renae Geier","role":"Senior Scientist, Genomics, Armata Pharmaceuticals (presenter)"}],"products":["AP-SA02"],"companies":[{"name":"Armata Pharmaceuticals, Inc.","ticker":"ARMP","relationship":"filer/issuer"},{"name":"LifeSci Advisors, LLC","relationship":"investor relations"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-22T08:01:40.575Z","global_importance":18,"audience_relevance":12,"importance_components":{"tickerTier":"micro-cap clinical-stage biotech","eventGravity":"conference-data-presentation","sectorWeight":"healthcare","issuerAuthored":true,"newClinicalData":false,"programStageContext":"Phase 3-ready lead asset, supportive but incremental data"}},"durationMs":125443,"modelName":"glm-5.3-flash"}}